ArticleOncogene2025
Vimentin intermediate filaments orchestrate DNA nonhomologous end joining repair and lipolysis after DNA damage.
Article in Oncogene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Review
- ATGL sensitizes hepatocellular carcinoma cells to genotoxic drugs by modulating p53 acetylation/phosphorylation status.Cell death discovery · 2026Article
- Unraveling the molecular mechanisms of vimentin interaction with G-quadruplex repeats.Nucleic acids research · 2026Article
- Targeting the Vim-PGIHuman mutation · 2026Article
- Next Generation DNA Damage Response Inhibitors: Harnessing Nanocarriers and Tumor Microenvironment for Precision Cancer Therapy.Oncology research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Vimentin is a major component of intermediate filaments (IFs) within the three cytoskeletal systems, alongside actin filaments and microtubules. Spanning from the plasma membrane to the nuclear lamina, vimentin IFs form a cage-like network surrounding the nucleus, and modulate cell mechanics, migration and signaling. In this study, we show that vimentin depletion leads to accumulation of endogenous DNA damage. Interestingly, vimentin is associated with Ku proteins that sense DNA double strand breaks (DSB) and mediate nonhomologous end joining (NHEJ) repair. Depletion of vimentin impairs NHEJ repair, in line with reduced recruitment of Ku proteins to DNA damage sites and deficient activation of DNA-dependent protein kinase catalytic subunit (DNA-PKcs). Beyond its involvement in DSB repair, our research also uncovers the role of vimentin in modulating lipolysis following DNA damage. We show that DNA damage reduces lipid droplet contents via adipose triglyceride lipase (ATGL). Vimentin binds to and suppresses ATGL in lipolysis. Moreover, DNA-PKcs modulates ATGL and DNA damage-induced lipolysis via vimentin. Targeting vimentin leads to DNA damage hypersensitivity, suggesting its potential in cancer therapy. Taken together, our findings elucidate new roles of vimentin in orchestrating DNA repair and lipolysis, shedding light on the involvement of vimentin IF in cell homeostasis, cancer resistance, and metabolic regulation.
Indexed as
Identifiers
40550847What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.